Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine
Colon Cancer, Inflammatory Bowel Diseases, Diverticulitis
About this trial
This is an interventional treatment trial for Colon Cancer
Eligibility Criteria
Inclusion Criteria:
- patients scheduled to undergo laparoscopic colonic resection
Exclusion Criteria:
- patients who have trouble to understand, read or communicate either in French or in English
- dementia
- patients suffering from severe physical disability (arthritis, neuromuscular dysfunction, stroke, paraplegia) or inability to walk or conduct daily activity
- patients suffering from severe cardiac or respiratory disease (status ASA IV)
- patients suffering from metastatic carcinoma
- patients who have a history of chemoradiation within the six months preceding surgery
- allergy to lidocaine
- morbid obesity
Sites / Locations
- Montreal General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
LIDOCAINE group
Epidural Group
PCA group
LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.